Update on HPV Vaccination

  • Anshul Grover


Human papillomavirus is a sexually transmitted virus responsible for cancer of the cervix, vagina, vulva, anus, penis, oral cavity, and oropharynx. Primary prevention of this infection by HPV vaccination can prevent most cases of cervical cancer in women, if given before sexual debut. Though the quadrivalent and bivalent vaccines were approved by the FDA in 2006 and 2009, respectively, the 9-valent vaccine was approved in 2017. This chapter will discuss the newly available nonavalent HPV vaccine (its rationale, efficacy, and cost-effectiveness comparable to older vaccines), changes in dosage schedules, safety updates, and under research therapeutic vaccines.


HPV Vaccination Bivalent Quadrivalent Nonavalent vaccine Therapeutic vaccine 


  1. 1.
    National Advisory Committee on Immunization. Update on human papillomavirus (HPV) vaccines. An advisory committee statement. Commun Dis Rep. 2012;38:1–62.Google Scholar
  2. 2.
    Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus type shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278–85.CrossRefGoogle Scholar
  3. 3.
    World Health Organization. Human papillomavirus vaccines. WHO position paper, May 2017 [PDF]. Wkl Epidemiol Rec 19. 12 May 2017;92:241–68.Google Scholar
  4. 4.
    World Health Organization. The immunological basis for immunization series. Module 19: human papillomavirus infection [PDF]. May 2011.Google Scholar
  5. 5.
    Kaarthigeyan K. Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol. 2012;33(1):7–12.CrossRefGoogle Scholar
  6. 6.
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–65.CrossRefGoogle Scholar
  7. 7.
    Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years follow up. Br J Cancer. 2006;95:1459–66.CrossRefGoogle Scholar
  8. 8.
    Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia—nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106(3):djt460.CrossRefGoogle Scholar
  9. 9.
    Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infections and disease in males. N Engl J Med. 2011;364(5):401–11.CrossRefGoogle Scholar
  10. 10.
    Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544–7.CrossRefGoogle Scholar
  11. 11.
    Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.CrossRefGoogle Scholar
  12. 12.
    de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56.CrossRefGoogle Scholar
  13. 13.
    Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomark Prev. 2014;23:1997–2008.CrossRefGoogle Scholar
  14. 14.
    Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013;132:854–67.CrossRefGoogle Scholar
  15. 15.
    Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasms in women. N Engl J Med. 2015;372:711–23.CrossRefGoogle Scholar
  16. 16.
    Pretet JL, Jacquard AC, Carcopino X, Charlot JF, Bouhour D, Kantelip B, et al. Human papilloma virus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer. 2008;122(2):428–32.CrossRefGoogle Scholar
  17. 17.
    Pretet JL, Jacquard AC, Carcopino X, Monnier-Benoit S, Averous G, Soubeyrand B, et al. Human papilloma virus (HPV) genotype distribution in high grade lesions in France: EDITH study. Int J Cancer. 2008;122(2):424–7.CrossRefGoogle Scholar
  18. 18.
    Abramowitz L, Jacquard AC, Jaroud F, Haesebaert J, Siproudhis L, Pradat P, et al. Human papillomavirus distribution in anal cancer in France: the EDITH V study. Int J Cancer. 2011;129(2):433–9.CrossRefGoogle Scholar
  19. 19.
    St Guily JL, Jacquard AC, Prétet JL, Haesebaert J, Beby-Defaux A, Clavel C, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France – the EDITH study. J Clin Virol. 2011;51(2):100–4.CrossRefGoogle Scholar
  20. 20.
    Riethmuller D, Jacquard AC, St L, Gully J, Aubin F. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health. 2015;15:453.CrossRefGoogle Scholar
  21. 21.
    Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analysis of a nine valent vaccine in women aged 16-26 years: a randomized, double blind trial. Lancet. 2017;390(10108):2143–59.CrossRefGoogle Scholar
  22. 22.
    Markowitz LE, Hariri S, Lin C. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in United States, National Health and Nutrition Examination Survey, 2003-2010. J Infect Dis. 2013;208(3):385–93.CrossRefGoogle Scholar
  23. 23.
    Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following national vaccination program. J Infect Dis. 2012;206:1645–51.CrossRefGoogle Scholar
  24. 24.
    World Health Organization. Comprehensive cervical cancer prevention and control: a healthier future for girls and women. Geneva: World Health Organization; 2013.Google Scholar
  25. 25.
    Global immunization data: WHO 2015. Available from: Accessed 15 Nov 2015.
  26. 26.
    Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10:845.CrossRefGoogle Scholar
  27. 27.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443.CrossRefGoogle Scholar
  28. 28.
    Bogaards JA, Wallinga J, Brakenhoff RH, et al. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: Bayesian evidence synthesis. BMJ. 2015;350:h2016.CrossRefGoogle Scholar
  29. 29.
    Department of Health and Public Health England. JVCI interim position statement on HPV vaccination of men who had sex with men. 2014. Available from:
  30. 30.
    Zou H, Tabrizi SN, Grulich AE, Garland SM, Hocking JS, Bradshaw CS, et al. Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. J Infect Dis. 2014;209:642–51.CrossRefGoogle Scholar
  31. 31.
    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB, Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med. 2017;166:209.CrossRefGoogle Scholar
  32. 32.
    Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014;63:1.PubMedGoogle Scholar
  33. 33.
    Printz C. One HPV vaccine dose may prevent cervical cancer. Cancer. 2014;120:772–3.CrossRefGoogle Scholar
  34. 34.
    Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 ASO4-adjuncted vaccine: combined analysis of data from the Costa Rica vaccine and PATRICIA trials. Lancet Oncol. 2015;16:775–86.CrossRefGoogle Scholar
  35. 35.
    Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 ASO4-adjuvanted vaccine administered as 2 dose schedule compared to the licensed 3 dose schedule: results from a randomised study. Hum Vaccin. 2011;7:1374–86.CrossRefGoogle Scholar
  36. 36.
    Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013;6:1242–50.CrossRefGoogle Scholar
  37. 37.
    Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principal evaluation of efficacy of fewer than three doses of a bivalent HPV 16/18 vaccine. J Natl Cancer Inst. 2011;103:1444–51.CrossRefGoogle Scholar
  38. 38.
    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for the vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309.CrossRefGoogle Scholar
  39. 39.
    World Health Organization. Global advisory committee on vaccine safety statement on the continued safety of HPV vaccination. 12 March 2014.
  40. 40.
    Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccine. Vaccine. 2012;30(suppl 5):F123–38.CrossRefGoogle Scholar
  41. 41.
    Rosales R, Lopez-Conteras M, Rosales C, Magallanes-Molina JR, Gonzalez-Vergara R, Arroyo-Cazarez JM, et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther. 2014;25(12):1035–49.CrossRefGoogle Scholar
  42. 42.
    REVEAL 1 (evaluation of VGX-3100 and electroporation for the treatment of cervical HSIL).

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Anshul Grover
    • 1
  1. 1.Specialist, Department of Obstetrics and GynaecologyBabu Jagjivan Ram Memorial HospitalNew DelhiIndia

Personalised recommendations